Pepdexpepdex
My Stack
← Back to peptides
Comparison

VK2735 vs Retatrutide

VK2735 vs Retatrutide: dual vs triple agonist, the oral option vs the strongest trial numbers.

The verdict

Two of the most-watched next-generation weight-loss compounds, both still in trials. Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) with the biggest weight-loss numbers in the class. VK2735 is a dual agonist (GLP-1 + GIP), and its real draw is the oral version rather than raw effect size. Neither is approved. If the headline is maximum trial weight loss, Retatrutide leads. If it is a needle-free future, VK2735 is the one to watch. For now both are investigational and source quality is the real risk.

№ 004
VK2735
Fat LossEvidence: Moderate

VK2735 is an experimental weight-loss drug from Viking Therapeutics. It works on two gut-hormone receptors (GLP-1 and GIP) to cut appetite, the same combo as Tirzepatide. The notable part is the pill version: in early trials a once-daily tablet got close to the results of the injection. It is still in testing and not approved.

Onset
80
Documentation
95
Side intensity
100
Popularity
55
№ 003
Retatrutide
Fat LossEvidence: Moderate

Retatrutide is the newest weight-loss compound in development at Eli Lilly. It's a stronger cousin of Tirzepatide (Mounjaro / Zepbound) and pulls bigger weight loss in trials, often 20%+ of body weight. One injection per week. Side effects are real, especially in the first few weeks.

Onset
80
Documentation
95
Side intensity
100
Popularity
90
Side-by-side
Field
Left
Right
Category
Fat Loss
Fat Loss
Half-life
Long-acting; dosed once-weekly (subcutaneous) in trials
~6 days
Route
Subcutaneous (weekly) or oral (daily), both investigational
Subcutaneous
Schedule
Weekly (injectable) or once-daily (oral) in trials
Once weekly
Cycle length
Trial protocols ran 13 weeks; no established real-world cycle
Open-ended, titrate over 4-6 months
Dose
No approved human dosing. In Phase 2, the injectable (the VENTURE program) was titrated weekly and an oral Phase 2 ran once-daily, both over 13 weeks. Outside a clinical trial there is no established protocol, and access is trial-only.
Start 2mg sub-q weekly. Titrate by 2mg every 4 weeks based on tolerance. Trials went up to 12mg; most users plateau benefit at 8-12mg.
FDA
Investigational. The injectable is in Phase 3 (begun 2025); the oral form is expected to enter Phase 3 around late 2026. Pivotal readouts are not expected before 2027. Not approved.
Investigational. In Phase 3 trials with Eli Lilly. Not yet approved.
WADA
Not listed
Not listed
Natty?
Not natty
Not natty
Prescribed
Not available by prescription. Access is trial-only through Viking Therapeutics' clinical program.
Not yet available by prescription. Trial-only access through Lilly's clinical program.
Top side effects
Nausea (most common, usually mild to moderate); Vomiting; Diarrhea or constipation
Nausea (especially first 2 weeks of each titration step); Constipation or diarrhea; Fatigue / lethargy

Which one should you pick?

Pick VK2735 if people following the oral-glp-1 race who want a needle-free option or users tracking next-generation weight-loss compounds before approval.

Pick Retatrutide if people plateaued on tirzepatide or users targeting >15% body weight loss.

AI Coach · free

Still torn between VK2735 and Retatrutide?

The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.

Ask the Coach: VK2735 vs Retatrutide →
Full entry
№ 004 VK2735 →
Full entry
№ 003 Retatrutide →